Lilly has announced positive first data from two phase III trials, showing that tirzepatide led to significant reductions in HbA1c and body weight reductions from baseline in people with type 2 diabetes.
The positive results from the trials demonstrate tirzepatide’s potential to lower HbA1C and body weight in people with type 2 diabetes who are at the point in their treatment journey where they would progress to an injectable therapy.
In the 52-week SURPASS-3 study, the highest dose of tirzepatide (15mg) reduced HbA1C by 2.37% and body weight by 12.9kg (28.4lb., 13.9%) vs HbA1C reduction of 1.34% and weight gain of 2.3kg with insulin degludec. More data and information on the safety profile are included in the attached release.
Tirzepatide is a novel investigational glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that integrates the actions of both incretins into a single molecule, representing a new class of medicines being studied for the treatment of type 2 diabetes. GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight.
Mike Mason, president, Lilly Diabetes said: “Tirzepatide delivered impressive HbA1C and body weight reductions in both studies and continued to achieve consistent efficacy and safety results in people living with type 2 diabetes, regardless of 2 how long they have had the condition. Significantly lowering HbA1C levels and weight are high priorities throughout the type 2 diabetes treatment journey, and the results we have seen from three SURPASS studies to date fuel our belief in tirzepatide’s ability to meet those needs.”